Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: A randomized clinical trial

Journal of Glaucoma

Volumn 23, Issue 7, 2014, Pages 461-463

  Katayama, Bianka Y N Y ^a   Bonini Filho, Marco A ^a   Messias, André M V ^a   Paula, Jayter S ^a   Martin, Luiz F T ^a   Costa, Rogério ^a,b   Jorge, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital de Olhos de Araraquara   (Brazil)

Author keywords

acetazolamide; bevacizumab; brimonidine; intraocular pressure; paracentesis

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; BRIMONIDINE; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; MONOCLONAL ANTIBODY; QUINOXALINE DERIVATIVE;

ANTERIOR CHAMBER PARACENTESIS; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; PARACENTESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; AGED; ANTERIOR EYE CHAMBER; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; ORAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

ACETAZOLAMIDE; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; ANGIOGENESIS INHIBITORS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PARACENTESIS; QUINOXALINES; TONOMETRY, OCULAR;

EID: 84907423645     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3182948476     Document Type: Article

References (22)

1. Falkenstein IA, Cheng L,Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina. 2007;27:701-706
2. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2007;23: 181-185
3. Frenkel RE, Mani L, Toler AR, et al. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034-1035
4. Hariprasad SM, Shah GK, Blinder KJ. Short-Term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol. 2006;141:200-201
5. Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol. 2007;17:776-779
6. Zamvar U, Dhillon B. Postoperative IOP prophylaxis practice following uncomplicated cataract surgery: A UK-wide consultant survey. BMC Ophthalmol. 2005;5:24
7. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. Am J Ophthalmol. 1954;37:13-15
8. Maus TL, Larsson LI, McLaren JW, et al. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45-49
9. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93:232-237
10. Yoles E, Wheeler LA, Schwartz M. Alpha2-Adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65-73
11. David R. Brimonidine (Alphagan): A clinical profile four years after launch. Eur J Ophthalmol. 2001;11(suppl 2):S72-S77
12. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847-852
13. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48(suppl 1):S47-S51
14. Robin AL. The role of alpha-Agonists in glaucoma therapy. Curr Opin Ophthalmol. 1997;8:42-49
15. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517
16. Rolle T, Cipullo D, Vizzeri GM, et al. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: Brimonidine and latanoprost. Preliminary results. Acta Ophthalmol Scand Suppl. 2000;50-52
17. Oshika T, Araie M. Time course of changes in aqueous protein concentration and flow rate after oral acetazolamide. Invest Ophthalmol Vis Sci. 1990;31:527-534
18. Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009; 24:100-105
19. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007;27:1044-1047
20. Tsui YP, Chiang CC, Tsai YY. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008;43:239, author reply 239-240
21. Huang WC, Lin JM, Chiang CC, et al. Necessity of paracentesis before or after intravitreal injection of bevacizumab. Arch Ophthalmol. 2008;126:1314-1315, author reply 1315
22. Lin JM, Tsai YY, Chiu YT, et al. Paracentesis before or after intravitreal injection of triamcinolone acetonide and its necessity?. Am J Ophthalmol. 2006;141:985-986, author reply 986